Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10489149" target="_blank" >RIV/00064165:_____/24:10489149 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/24:10489149

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D0m--kXCh5" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=D0m--kXCh5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/17512433.2024.2432500" target="_blank" >10.1080/17512433.2024.2432500</a>

Result language

angličtina

Original language name

Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview

Original language description

Introduction: ANCA-associated vasculitis (AAV) is a rare, life-threatening disease which may result in serious pulmonary and kidney damage. Cyclophosphamide or rituximab and high-dose glucocorticoids significantly improved patient outcomes, but at the expense of severe complications. Moreover, many patients still relapse and bear a significant burden of both disease- and treatment-related complications. Alternative complement pathway and C5a receptor signaling were demonstrated to play an important role in AAV pathogenesis. Avacopan is selective C5a receptor inhibitor successfully tested in renal AAV as glucocorticoid-sparing agent. Areas covered: Pharmacokinetic/pharmacodynamic properties, clinical efficacy and safety of avacopan, available clinical trials and real-world experience with avacopan. Expert opinion: In the phase 3 trial avacopan was shown to be non-inferior at six and superior at 12 months compared to high-dose glucocorticoids and either cyclophosphamide or rituximab in patients with active AAV. Treatment with avacopan was well tolerated and associated with improved quality of life. In patients with severe renal AAV, renal function improved more in avacopan-treated than in high-dose glucocorticoid-treated patients. Avacopan could thus replace high-dose glucocorticoids to avoid glucocorticoid-related toxicity and to improve long term renal outcome. As avacopan is CYP 3A4 inhibitor and substrate, drug-drug interactions must be considered during the treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Expert Review of Clinical Pharmacology

ISSN

1751-2433

e-ISSN

1751-2441

Volume of the periodical

17

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

15

Pages from-to

1099-1113

UT code for WoS article

001367374700001

EID of the result in the Scopus database

2-s2.0-85210761951